EP3450433A4 - Substituiertes purinderivat - Google Patents

Substituiertes purinderivat Download PDF

Info

Publication number: EP3450433A4
Authority: EP; European Patent Office
Prior art keywords: purine; substituted derivative; derivative; substituted
Prior art date: 2016-04-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP17789569.5A

Other languages

English (en)

French (fr)

Other versions

EP3450433B1 (de

EP3450433A1 (de

Inventor

Shingo Tojo

Yoshiaki Isobe

Eiji IDEUE

Hiroaki Fujiwara

Daisuke Urabe

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sumitomo Pharma Co Ltd

Original Assignee

Sumitomo Dainippon Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-26

Filing date

2017-04-25

Publication date

2019-10-16

2017-04-25 Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd

2019-03-06 Publication of EP3450433A1 publication Critical patent/EP3450433A1/de

2019-10-16 Publication of EP3450433A4 publication Critical patent/EP3450433A4/de

2021-08-18 Application granted granted Critical

2021-08-18 Publication of EP3450433B1 publication Critical patent/EP3450433B1/de

Status Active legal-status Critical Current

2037-04-25 Anticipated expiration legal-status Critical

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Transplantation (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

EP17789569.5A 2016-04-26 2017-04-25 Purin-derivate als tlr7 inhibitoren zur behandlung von z.b. systemischer lupus erythematodes Active EP3450433B1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2016087656		2016-04-26
PCT/JP2017/016445 WO2017188287A1 (ja)	2016-04-26	2017-04-25	置換プリン誘導体

Publications (3)

Publication Number	Publication Date
EP3450433A1 EP3450433A1 (de)	2019-03-06
EP3450433A4 true EP3450433A4 (de)	2019-10-16
EP3450433B1 EP3450433B1 (de)	2021-08-18

Family

ID=60159663

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17789569.5A Active EP3450433B1 (de)	2016-04-26	2017-04-25	Purin-derivate als tlr7 inhibitoren zur behandlung von z.b. systemischer lupus erythematodes

Country Status (6)

Country	Link
US (1)	US10703755B2 (de)
EP (1)	EP3450433B1 (de)
JP (1)	JP6964072B2 (de)
CA (1)	CA3021947A1 (de)
TW (1)	TWI746545B (de)
WO (1)	WO2017188287A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2021035910A (ja) *	2017-11-01	2021-03-04	大日本住友製薬株式会社	置換プリン化合物
CN110317202B (zh) *	2018-03-30	2021-12-24	江苏恒瑞医药股份有限公司	氰基吡咯并杂芳基类衍生物、其制备方法及其在医药上的应用
TW202126658A (zh) *	2019-09-29	2021-07-16	大陸商江蘇恆瑞醫藥股份有限公司	吡咯并雜芳基衍生物或其偶聯物、其製備方法及其應用
WO2021154662A1 (en) *	2020-01-27	2021-08-05	Bristol-Myers Squibb Company	1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097105A1 (de) *	2020-01-27	2022-12-07	Bristol-Myers Squibb Company	1h-pyrazolo[4,3-d]pyrimidinverbindungen als toll-like rezeptor 7 (tlr7)-agonisten
CN114276351B (zh) *	2020-09-27	2023-06-16	江苏恒瑞医药股份有限公司	含氮杂环类衍生物、其制备方法及其在医药上的应用
WO2022156678A1 (zh) *	2021-01-20	2022-07-28	上海维申医药有限公司	大环tlr7激动剂、其制备方法、药物组合物及其用途
KR20230171469A (ko)	2021-04-16	2023-12-20	길리애드 사이언시즈, 인코포레이티드	티에노피롤 화합물
EP4398989A1 (de)	2021-09-10	2024-07-17	Gilead Sciences, Inc.	Thienopyrrolverbindungen
WO2024105159A1 (en) *	2022-11-16	2024-05-23	University Of Zurich	Ligands of the m6a-rna readers
CN118724963A (zh) *	2023-03-30	2024-10-01	浙江养生堂天然药物研究所有限公司	含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1688599A (en)	1998-01-05	1999-07-26	Eisai Co. Ltd.	Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
US6841549B1 (en) *	1999-07-02	2005-01-11	Eisai Co., Ltd.	Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
DK1401837T3 (da) *	2001-06-29	2005-11-07	Cv Therapeutics Inc	Purinderivater som A2B-adenosinreceptorantagonister
WO2003006465A1 (en) *	2001-07-13	2003-01-23	Cv Therapeutics, Inc.	Partial and full agonist of a adenosine receptors
ES2279903T3 (es) *	2001-12-18	2007-09-01	Cv Therapeutics, Inc.	Antagonistas del receptor a2a de adenosina.
JP2007504232A (ja) *	2003-09-05	2007-03-01	アナディスファーマシューティカルズインク	Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
AU2006242920A1 (en) *	2005-05-04	2006-11-09	Pfizer Limited	2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
CA2691444C (en) *	2007-06-29	2016-06-14	Gilead Sciences, Inc.	Purine derivatives and their use as modulators of toll-like receptor 7
WO2009052310A1 (en)	2007-10-16	2009-04-23	Cv Therapeutics, Inc	A3 adenosine receptor antagonists
AU2008312444B2 (en) *	2007-10-18	2014-02-06	Bavarian Nordic A/S	Use of MVA to treat prostate cancer
US8785453B2 (en) *	2009-11-13	2014-07-22	Green Cross Corporation	Arylpiperazine-containing purine derivatives and uses thereof

2017
- 2017-04-25 JP JP2018514647A patent/JP6964072B2/ja not_active Expired - Fee Related
- 2017-04-25 US US16/095,822 patent/US10703755B2/en not_active Expired - Fee Related
- 2017-04-25 TW TW106113800A patent/TWI746545B/zh not_active IP Right Cessation
- 2017-04-25 CA CA3021947A patent/CA3021947A1/en active Pending
- 2017-04-25 WO PCT/JP2017/016445 patent/WO2017188287A1/ja not_active Ceased
- 2017-04-25 EP EP17789569.5A patent/EP3450433B1/de active Active

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number	Publication date
US20190169191A1 (en)	2019-06-06
WO2017188287A1 (ja)	2017-11-02
US10703755B2 (en)	2020-07-07
CA3021947A1 (en)	2017-11-02
JPWO2017188287A1 (ja)	2019-02-28
TWI746545B (zh)	2021-11-21
JP6964072B2 (ja)	2021-11-10
EP3450433B1 (de)	2021-08-18
EP3450433A1 (de)	2019-03-06
TW201739748A (zh)	2017-11-16

Legal Events

Date	Code	Title	Description
2017-11-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2019-02-01	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2019-02-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-03-06	17P	Request for examination filed	Effective date: 20181101
2019-03-06	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-03-06	AX	Request for extension of the european patent	Extension state: BA ME
2019-07-31	DAV	Request for validation of the european patent (deleted)
2019-07-31	DAX	Request for extension of the european patent (deleted)
2019-10-16	A4	Supplementary search report drawn up and despatched	Effective date: 20190916
2019-10-16	RIC1	Information provided on ipc code assigned before grant	Ipc: C07D 473/28 20060101ALI20190910BHEP Ipc: C07D 473/34 20060101ALI20190910BHEP Ipc: C07D 473/40 20060101ALI20190910BHEP Ipc: C07D 473/18 20060101AFI20190910BHEP Ipc: A61K 31/52 20060101ALI20190910BHEP Ipc: C07D 473/16 20060101ALI20190910BHEP Ipc: A61P 37/06 20060101ALI20190910BHEP
2020-07-20	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602017044366 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C07D0473220000 Ipc: C07D0473180000
2020-08-26	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/5377 20060101ALI20200720BHEP Ipc: A61K 31/52 20060101ALI20200720BHEP Ipc: C07D 473/34 20060101ALI20200720BHEP Ipc: C07D 473/16 20060101ALI20200720BHEP Ipc: C07D 473/28 20060101ALI20200720BHEP Ipc: A61P 37/06 20060101ALI20200720BHEP Ipc: C07D 473/18 20060101AFI20200720BHEP Ipc: C07D 473/40 20060101ALI20200720BHEP
2020-09-15	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2020-09-15	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2020-10-14	INTG	Intention to grant announced	Effective date: 20200916
2021-01-25	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2021-01-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2021-03-03	INTC	Intention to grant announced (deleted)
2021-03-23	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2021-03-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2021-04-21	INTG	Intention to grant announced	Effective date: 20210324
2021-07-14	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2021-07-16	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2021-07-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2021-08-18	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2021-08-18	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2021-08-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2021-09-09	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602017044366 Country of ref document: DE
2021-09-15	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D Ref country code: AT Ref legal event code: REF Ref document number: 1421542 Country of ref document: AT Kind code of ref document: T Effective date: 20210915
2021-12-10	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG9D
2021-12-22	REG	Reference to a national code	Ref country code: NL Ref legal event code: MP Effective date: 20210818
2022-01-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 1421542 Country of ref document: AT Kind code of ref document: T Effective date: 20210818
2022-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211118 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211118 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211220 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818
2022-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211119
2022-04-04	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818
2022-04-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818
2022-05-19	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602017044366 Country of ref document: DE
2022-06-01	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818
2022-06-24	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2022-06-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2022-07-27	26N	No opposition filed	Effective date: 20220519
2022-07-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818
2022-07-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20220425 Year of fee payment: 6 Ref country code: FR Payment date: 20220421 Year of fee payment: 6 Ref country code: DE Payment date: 20220420 Year of fee payment: 6
2022-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818
2022-08-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20220421 Year of fee payment: 6
2023-01-04	REG	Reference to a national code	Ref country code: BE Ref legal event code: MM Effective date: 20220430
2023-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220425
2023-02-15	REG	Reference to a national code	Ref country code: DE Ref legal event code: R081 Ref document number: 602017044366 Country of ref document: DE Owner name: SUMITOMO PHARMA CO., LTD., JP Free format text: FORMER OWNER: SUMITOMO DAINIPPON PHARMA CO., LTD., OSAKA, JP
2023-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220430
2023-04-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220425
2023-11-03	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 602017044366 Country of ref document: DE
2023-11-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2023-12-27	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20230425
2024-01-18	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230425
2024-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231103 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230425
2024-03-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20170425
2024-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818
2024-06-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818
2024-09-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210818

Publication	Publication Date	Title
PL3507418T3 (pl)	2025-11-12	Sposoby biopochodnej derywatyzacji powierzchni celulozowych
DK3319956T3 (da)	2021-03-29	Substituerede oxopyridinderivater
EP3420388A4 (de)	2019-11-27	Pupillenentzerrung
EP3509581A4 (de)	2020-04-08	Formulierungen von (r
EP3450433A4 (de)	2019-10-16	Substituiertes purinderivat
IL265166B (en)	2021-09-30	Anti-influenza virus pyrimidine derivatives
PT3645518T (pt)	2021-08-23	Síntese de omecamtiv mecarbil
PT3457851T (pt)	2021-09-28	Derivados de sobetiroma
EP3406336A4 (de)	2019-07-10	Nanofolie vom kern-hülle-struktur-typ
EP3360010A4 (de)	2019-06-19	Bi-photonen mit abstimmbarer quelle
IL272851A (en)	2020-04-30	Methods of using dipivefrin
LT3402792T (lt)	2021-12-10	Chinolin-2-ono dariniai
EP3564216A4 (de)	2020-05-27	Pyrimidinderivat
DK3283210T3 (da)	2021-11-22	Fremgangsmåde
LT3371168T (lt)	2020-10-12	Indolin-2-ono dariniai
EP3309163A4 (de)	2019-01-09	Substituiertes dihydropyrrolopyrazolderivat
FR3023290B1 (fr)	2016-08-19	Derives de flavaglines
PT3143018T (pt)	2021-06-01	Derivados da caboxamida
LT3445743T (lt)	2021-09-27	Aminorūgšties darinio provaistas
EP3333163A4 (de)	2019-01-09	Substituiertes guanidinderivat
IL250613B (en)	2020-07-30	Substituted bicyclic compounds
EP3328991A4 (de)	2019-04-10	Biosynthese von polyketiden
EP3277701A4 (de)	2019-03-06	Synthese von desosaminen
IL254502A0 (en)	2017-11-30	Solid forms of menaquinols
EP3444345C0 (de)	2024-07-10	Mikrorna-143-derivat